Clopidogrel treatment in a patient with ticlopidine-induced hepatitis following percutaneous coronary stenting

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Thienopyridines are vital antiplatelet medications for cardiovascular and cerebrovascular conditions.
• Antiplatelet therapy is crucial post-percutaneous coronary stenting.
• Drug-induced liver injury from antiplatelets, though rare, presents clinical challenges.

Observation:

• A patient with a history of ticlopidine-induced hepatitis required ongoing antiplatelet treatment.
• Liver biopsy confirmed hepatitis attributed to ticlopidine.
• Clopidogrel was prescribed despite the prior adverse reaction.

Findings:

• The case demonstrates the successful, albeit cautious, use of clopidogrel in a patient with a history of thienopyridine-induced liver injury.
• No immediate adverse hepatic events were noted with clopidogrel in this specific instance.
• This highlights the potential for cross-reactivity or distinct tolerability profiles within the thienopyridine class.

Implications:

• Physicians must carefully weigh the risks and benefits of antiplatelet agents in patients with a history of drug-induced reactions.
• This case provides valuable insight for managing patients with absolute antiplatelet needs and prior adverse drug events.
• Further research into predicting and managing antiplatelet-related hepatotoxicity is warranted.